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Abstract
Background: Retinal hemorrhages have been described as a component of high altitude retinopathy (HAR) in association
with altitude illness. In this prospective high altitude study, we aimed to gain new insights into the pathophysiology of HAR
and explored whether HAR could be a valid early indicator of altitude illness.
Methodology/Principal Findings: 28 mountaineers were randomly assigned to two ascent profiles during a research
expedition to Mt. Muztagh Ata (7546 m/24,751 ft). Digital fundus photographs were taken prior to expedition at 490 m
(1,607 ft), during expedition at 4497 m (14,750 ft = base camp), 5533 m (18,148 ft), 6265 m (20,549 ft), 6865 m (22,517 ft)
and 4.5 months thereafter at 490 m. Number, size and time of occurrence of hemorrhages were recorded. Oxygen
saturation (SpO2) and hematocrit were also assessed. 79% of all climbers exhibited retinal hemorrhages during the
expedition. Number and area of retinal bleeding increased moderately to medium altitudes (6265 m). Most retinal
hemorrhages were detected after return to base camp from a high altitude. No post-expeditional ophthalmic sequelae were
detected. Significant negative (SpO2 Beta:20.4, p,0.001) and positive (hematocrit Beta: 0.2, p = 0.002, time at altitude Beta:
0.33, p = 0.003) correlations with hemorrhages were found.
Conclusions/Significance: When closely examined, a very large amount of climbers exhibit retinal hemorrhages during
exposure to high altitudes. The incidence of retinal hemorrhages may be greater than previously appreciated as a definite
time lag was observed between highest altitude reached and development of retinal bleeding. Retinal hemorrhages should
not be considered warning signs of impending severe altitude illness due to their delayed appearance.
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Introduction
Altitude-related illness, which includes acute mountain sickness
(AMS), high altitude cerebral edema (HACE) and high altitude
retinopathy (HAR)[1,2], occurs in unacclimatized individuals
exposed to hypobaric hypoxia at high altitudes.[3] Independent
risk factors for the development of high altitude illness are the
altitude reached, individual susceptibility and rate of ascent.[4,5]
Climbers affected by AMS suffer from a variety of nonspecific
symptoms such as headache, nausea, insomnia, dizziness, lassitude
or fatigue.[6] In some mountaineers symptoms can progress and
develop into HACE, the end-stage of AMS, which is probably due
to hypoxia-induced increase in cerebral blood flow coupled with
decreased integrity of the blood-brain barrier and cytotoxic
edema.[7] It is diagnosed by detection of ataxia, altered
consciousness or both in a person with AMS. If not treated
accordingly, this illness is lethal.
Many individuals who ascend to heights above 3000 m develop
HAR, reported as engorgement and tortuosity of the retinal
vessels, and optic disc hyperemia and swelling, retinal hemor-
rhages, nerve fiber layer infarction, and even vitreous hemor-
rhage.[8] The regulation of the cerebral circulation has been
reported to behave similarly to that of the retinal vessels under
hyper- and hypoxic conditions.[9,10] Therefore common mech-
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anisms may play a role in the pathophysiology of HAR, AMS and
HACE. Whether HAR is potentially related to CNS dysfunction
at high altitudes is still a matter of debate.[11,12]
Clarke et al.[11] doubt that the appearance of isolated retinal
hemorrhages is a warning sign of impending cerebral edema. In
contradistinction, Wiedman and Tabin[12] indicated a possible
association between HAR and HACE. This hypothesis is
supported by recent studies showing that altered autoregulation
of the cerebral blood flow[13] and vasogenic cerebral edema[14]
may cause AMS and HACE.
The Muztagh Ata (7546 m/24,751 ft) medical research expe-
dition study was performed by researchers from the medical
specialties of pulmonology, neurology, hematology and ophthal-
mology. The overall aim of this prospective large scale study was
to assess hypoxic changes of the body in a holistic approach. Our
goal in this study was to gain new insights in the pathophysiology
of HAR by obtaining frequent field fundus photographs and
correlate potential ocular fundus abnormalities with concomitant
ocular changes as well as high altitude-associated cerebral
symptoms and signs. Finally, we explored whether HAR could
be a valid early indicator of altitude illness or even HACE.
Methods
Study design and outcomes
In this prospective, multidisciplinary study[5,15,16] 32 moun-
taineers were randomly assigned to two ascent profiles (Fig. 1)
during an expedition to Mt. Muztagh Ata (7546 m/24,751 ft) in
western China. Both ascent groups started the expedition at
3750 m/12,300 ft, then continued to base camp (BC1= 4497 m/
14,750 ft), camp 1 (C1= 5533 m/18,148 ft), camp 2 (C2=
6265 m/20,549 ft), camp 3 (C3= 6865 m/22,517 ft) and to the
summit (7546 m/24,751 ft) within 20 (group 1) and 19 (group 2)
days. Average ascent rates were 190 and 200 m/d (623 and
656 ft/d), respectively (Fig. 1). Included were healthy, physically
fit, experienced mountaineers of either gender and between 20 to
65 years of age without any ophthalmic pathology. They needed to
have reached at least C2 and had to have available fundus
photographs at second base camp (BC2) examination. Exclusion
criteria were any type of ocular, cardiac or respiratory disease, or a
history of high altitude pulmonary edema or high-altitude cerebral
edema (HACE) after a rapid ascent (,3 nights) to altitudes below
3500 m. Time to every new examination camp (in days) was
recorded from the start of the expedition above 3750 m/12,300 ft
( = time at altitude).
The study was approved by the Ethics Committee of the
University Hospital in Zurich, and adheres to the tenets of the
Declaration of Helsinki (1983 revision). All subjects gave written
consent prior to the examinations after having been informed of
the nature and goals of the research expedition.
General and ophthalmic examinations were performed 1 month
prior to the expedition (ZH1) and 4.5 months after return (ZH2),
at the University Hospital of Zurich (490 m/1607 ft).
Eye examinations included: digital fundus photography (in ZH:
Zeiss FF 450 plus camera, Carl Zeiss AG, Oberkochen, Germany;
on Mt Muztagh Ata: handheld fundus camera Genesis-D, Kowa
Inc., Tokyo, Japan). At every examination, 12 photographs were
taken of each eye according to a standardized protocol, where the
macula and the entire periphery were documented in a clockwise
manner at half-minute intervals. Number, size (in optic disc areas),
distance from center of optic disc (in optic disc diameters) to center
of hemorrhage, and altitude at which hemorrhages occurred were
assessed by two independent ophthalmologists. The custom made
program employed to measure size and distance of retinal
hemorrhages was developed in MATLAB (R2007a, The Math-
Works Inc., Natick MA; U.S.A.), and accounted for different
magnification between the cameras and image distortion due to
different angles while taking images of the fundus periphery. This
enabled direct comparison of retinal hemorrhages independent of
the employed fundus camera and zoom factor.
Figure 1. Ascent profile of both groups of climbers with indication of high camps and examination time points.
doi:10.1371/journal.pone.0011532.g001
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Ancillary ophthalmic examinations included: fluorescein angiog-
raphy, vessel diameter measurements of the temporal superior
branch retinal artery and vein (arbitrary units [AU]) as described
earlier,[16] and optic disc evaluation.[15] Furthermore, perifoveal
retinal blood flow measurements were performed utilizing the blue
field simulation (BFS-1000, Oculix Inc., Berwyn, USA) tech-
nique[16] resulting in time-averaged velocity (BFS-Vel mm/s) of
leukocytes. Subfoveal choroidal blood flow measurements were
done with a portable confocal laser Doppler flowmetry[17] (LDF)
system (Institut de Recherche en Ophtalmologie, Sion, Switzer-
land)[16] permitting localized blood flow measurements (LDF flow-
derived from velocity and volume in AU).[18] Intraocular pressure
measurements were performed with the portable Tono-Pen XL
(Reichert Inc., Depew, NY, U.S.A.).[19] Visual fields before and
after the climb were obtained with the dynamic strategy (G2)
program of a full-projection perimeter (Octopus 101; Haag-Streit
AG, Koeniz/Bern, Switzerland). Amsler grid self-evaluation of the
central visual field was performed individually every second day
during the climb and recorded in the personal diary.
Vital Parameters. Diastolic (PA.dia) and systolic (PA.sys)
brachial artery blood pressure were measured with a
sphygmomanometry device. Mean systemic blood pressure was
calculated as follows: PA.dia + (1/3)6(PA.sys 2 PA.dia). Perfusion
pressure of the eye resulted from subtracting intraocular pressure
(IOP) from 2/3 of the mean systemic blood pressure.[20]
Hematocrit was measured in capillary blood samples and values
were determined after centrifugation onsite (HAEMATOKRIT
2010, Hettich, Switzerland).
Daily oximetry was performed in the evening during rest in a
standing position with a finger pulse oximeter (Onyx 9500
SportStat, Nonin Medical Inc., Plymouth, MN, U.S.A.). Stable
values after at least 3 minutes were recorded.[5]
Cerebral acute mountain sickness (AMS-c) scores were assessed
daily utilizing the Environmental Symptom Questionnaire (ESQ
III).[15,21] A score of $0.7 reliably identifies a person with
AMS.[21] The AMS-c score reflects symptoms of altered cerebral
function in conjunction with the experience of being ill. Diagnosis
of HACE was made when headache and an AMS-c score of $0.7
were present either with change in mental status or with ataxia.
Drug intake was recorded. Intake of non steroidal anti-
inflammatory agents was allowed by protocol, whereas other
medication was taken only upon prescription by the independent
expedition physician.
Except for fluorescein angiography and full-field perimetry, all
climbers underwent all examinations mentioned above during the
expedition, on the subsequent day upon arrival at each new camp
(Fig. 1).
Statistical analysis
Data are expressed as mean 6 standard deviation (SD) if
normally distributed and as median with interquartile ranges if
distribution was shown not to be normal. Normality was determined
using the Kolmogorov-Smirnov test. Differences between the
groups were assessed using unpaired Student’s t-test with Welch
correction or the MannWhitney U test, where appropriate. Fisher’s
exact test was used to analyze whether there was a statistically
significant difference in the number of retinal hemorrhages and
number of Roth spots between both groups. Two separate multiple
regression analyses, including testing for collinearity were per-
formed to analyze relations between the number and total area of
hemorrhages and different predictors pertaining either to systemic
changes or to changes in ocular circulation parameters. A two sided
a-error (P-value) of less than 0.05 was prospectively defined as
statistically significant. Statistical analysis was performed with the
software Statistica 6 (StatSoft Inc., Tulsa, OK, U.S.A.) and SPSS
13.0 (SPSS Inc., Chicago, IL, USA).
Role of the funding source. Funding was utilized for device
and further mountaineering material acquisition in addition to
financing the great amount of logistics needed prior, during and
after the expedition. The study sponsors did not play any role in
design or implementation of the study.
Results
Four participants out of the 32 initially included in the
ophthalmology study were excluded because of incomplete data
collection during the expedition resulting in 28 mountaineers
available for analysis. Twenty-six climbers reached 6850 m and
Table 1. Summary of total number, total area of retinal hemorrhages (in optic disc areas) and percentage of climbers with
hemorrhages per group at different altitudes.
Altitude Group
Number of
climbers
examined
Number of climbers with
retinal hemorrhages
Total number of
hemorrhages observed
Total area of hemorrhages
observed (in disc areas)
Percentage
of climbers with
hemorrhages
ZH1 1 13 0 0 0.00 0
BC1 1 13 0 0 0.00 0
C1 1 13 0 0 0.00 0
C2 1 12 5 8 0.96 42
BC2 1 13 8 23 4.84 62
ZH2 1 13 0 0 0.00 0
ZH1 2 15 0 0 0.00 0
BC1 2 15 1 1 0.07 7
C1 2 15 4 5 0.37 27
C2 2 15 8 31 4.75 53
C3 2 15 11 32 6.83 73
BC2 2 15 14 56 8.77 93
ZH2 2 15 0 0 0.00 0
doi:10.1371/journal.pone.0011532.t001
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two (both from group 1) 6250 m as the maximum height during
the expedition; 17 mountaineers (9 in group 1 (Gr1), 8 in group 2
(Gr2)) reached the summit. Due to bad weather conditions, Gr1
had to descend from C2 to BC instead of the designated further
ascent to C3. Hence, BC2 examinations in Gr1 were performed
after the descent from C2 and due to lack of manpower only group
2 (Gr2) could be documented at C3 and BC2 at the end of the
expedition. There is no statistically significant difference between
groups 1 (n= 13) and 2 (n= 15) concerning age ([mean6SD]:
45612 and 4468, respectively) and gender (female:male: 2:11 and
4:11, respectively).
Of 28 mountaineers, 22 (79%) exhibited retinal hemorrhages in
at least one eye during the expedition. Details and an example can
be found in Table 1, Fig. 2(Panels A–C) and Fig. 3. An increase in
both number and area of hemorrhages in both groups occurred
during ascent to C2. In Gr2, although further ascending, the
number of hemorrhages stagnated whereas the area of bleeding
increased. In both groups the majority of hemorrhages (number
and area) were detected after descent to base camp. The total
number of hemorrhages increased by 288% (Gr1) and 175% (Gr2)
upon descent to BC2, whereas the total bleeding area increased by
480% (Gr1) and 130% (Gr2). The mean distance from the center
of the optic disc to the center of the hemorrhage was 1.560.8 disc
diameters in all climbers; no statistically significant differences
were detected between groups and altitudes. No hemorrhages
were sighted within the fovea.
No hemorrhages could be detected either before or after the
expedition. Roth spots were detected in 3 climbers in Gr1 and in 6
in Gr2 without a statistically significant difference between groups.
No changes in fluorescein angiography were found after the
expedition (ZH2) compared to initial normal examinations (ZH1).
Full-field perimetry results were unchanged at ZH2 compared to
ZH1. Neither metamorphopsia nor central scotomas were
recorded in Amsler grid tests. The only visual disturbances
reported were floaters by one participant in whom retinal bleeding
was so extensive that vitreous hemorrhage occurred. An overview
of changes in the systemic parameters (AMS-c, SpO2, perfusion
pressure and hematocrit) and drug intake is presented in Table 2.
There was no statistically significant difference in total area and
number of hemorrhages between groups at the same altitudes.
This allowed us to merge the data for further analysis.
Separate multiple regression analyses with total number of
hemorrhages per altitude per climber and also total area of
hemorrhages per altitude per climber as the dependent factors and
environmental and systemic changes within each climber (SpO2,
hematocrit, time at altitude, optic disc swelling, AMS-c score, age)
yielded partial correlation coefficient (Beta) and significance level
(p value) pairs noted in Table 3. Results of same analysis with
independent predictors SpO2 and ocular circulation parameters
(BFS-V, perfusion pressure, LDF-Flow, arterial diameter, venous
diameter) are also shown in Table 3. Collinearity testing did not
reveal significant results. Regression analysis of drug intake did not
yield a significant partial correlation to total number (Be-
ta =20.009, p = 0.14) or total area of hemorrhages (beta =20.08,
p = 0.19) when corrected for age, time at altitude and AMS-c
scores. Two climbers suffered from early HACE during the
expedition. A plot of their number and total area of hemorrhages
against those of the climbers without any signs of HACE did not
Figure 2. Graphs describing hemorrhages in both groups of
climbers at different altitudes. Panel A: total number of hemor-
rhages; panel B: total area of hemorrhages; panel C: percentage of
mountaineers with hemorrhages in at least 1 eye.
doi:10.1371/journal.pone.0011532.g002
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show any systematic deviation or obvious differences (data not
shown). The 9 climbers with Roth spots were also evaluated in
comparison to all others. They showed more (at C1 p= 0.003, C2
p= 0.008, BC2 p,0.001) and larger areas of retinal bleeding (at
C1 p= 0.025, C3 p=0.015, BC2 p=0.006) and had significantly
lower oxygen saturation levels at C1. No statistically significant
differences in hematocrit, AMS-c scores and age were found.
Discussion
A vast majority of climbers, namely 79%, exhibited retinal
hemorrhages during the expedition of which most were detected
only after descent from a high altitude. Our novel findings are
important since they indicate that retinal hemorrhages cannot be
considered as warning signs of severe altitude sickness. Further-
more, the data suggest that the incidence of retinal hemorrhages
may have been underestimated in previous studies.
Our climbers with very low oxygen saturation showed more
retinal bleeding throughout the expedition. Also, the higher the
ascent and the longer the duration at high altitudes, the higher was
the occurrence of retinal hemorrhages. This concurs with a study
by McFadden et al. revealing that subjects who developed HAR
during maximal exercise showed a lower SaO2 during exercise
than those who did not present with HAR at any time at high
altitude.[8] If the occurrence of retinal hemorrhages were an
immediate effect of the ascent (i.e., increasing hypoxia), many
more hemorrhages should have been detected during the ascent
(e.g. in group 2 from C2 to C3) as opposed to the surprising
increase in hemorrhages observed upon descent. Group 1 (Gr1)
exhibited fewer hemorrhages than group 2 (Gr2), possibly due to
Figure 3. Fundus photographs of a climber from group 1 showing the development of retinal hemorrhages during the course of
her climb. Note the white-centered hemorrhage localized at the temporal inferior branch of the retinal artery.
doi:10.1371/journal.pone.0011532.g003
Table 2. An overview of changes in the systemic parameters (AMS-c, SaO2 in %, mean arterial blood pressure in mmHg, perfusion
pressure in mmHg and hematocrit in %) and drug intake.
ZH1 BC1 C1 C2 C3 BC2 ZH2
AMS-c score 0 (0–0) 0 (0–0.88) 0.09 (0–5.6) 0.09 (0–2.42) 0.23 (0–1.38) 0 (0–0.18) 0 (0–0)
SpO2 9860.84 8462.56 7566.33 7366.04 6563.49 8764.87 9860.75
Perfusion Pressure 4567.44 4566.6 4866.21 4964.94 not available 4866.07 5063.91
Hematocrit not available 4463.12 4563.73 5064.22 not available not available 4362.12
Diamox 0 0 0 0 0 3 0
Adalat 0 0 0 0 0 1 0
Steroids 0 0 0 0 0 2 0
Ibuprofen 0 12 19 14 7 8 0
doi:10.1371/journal.pone.0011532.t002
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the fact that Gr1 had final examinations at BC2 after a lower
maximal altitude (C2) as compared to Gr2, in which the BC2
examinations were performed after the descent from C3. Our
hypothesis stating a correlation between the degree of hypoxia and
the number of hemorrhages is supported by the results of the
statistical analyses, including our multiple regression analysis. The
results strongly suggest a correlation between the degree of
hypoxia - severity and time of exposure - and the number of
hemorrhages: many more climbers in Gr2 (93%) - who had had
sustained longer and more extensive systemic hypoxia- showed
retinal hemorrhages at BC2 than in Gr1 (62%).
Independent of the amount of hypoxia, the time of occurrence
of retinal bleeding is delayed in relation to the ascent for both
groups (Fig. 2). Hypoxic damage to vascular endothelium and
delayed leakage of blood may be the reason for this phenomenon.
This is also the common explanation for the occurrence of white-
centered hemorrhages, which were detected in 9 of our
climbers.[22] These hemorrhages, also known as Roth spots[23]
can be found in patients with capillary fragility due to conditions
such as systemic infections, sepsis, bacterial endocarditis or
anemia. The common underlying etiology seems to be the result
of capillary rupture.[22] The white center within the area of
bleeding of a Roth spot has been shown histopathologically to
represent a fibrin-platelet thrombus. Duane et al. concluded that
this white thrombus is at the site of a vessel rupture.[24] Duane et
al.[24] and McFadden et al.[8] described the occurrence of Roth
spots at high altitudes. In our study mountaineers with Roth spots
had significantly lower SpO2 values. This supports the possible
etiology of retinal bleeding after a hypoxic insult to the retinal
vessels at high altitudes, which may cause a wall rupture after a
certain time lag.
Climbers with white-centered hemorrhages also had a larger
area of retinal bleeding than the others. Mountaineers with only
few and small hemorrhages either had no biomicroscopically
detectable thrombi or no vessel rupture. This observation may be
explained by a distinct pathophysiological process. Reperfusion
trauma occurring upon descent to a lower camp may contribute to
endothelial damage; induce diathesis and thereafter visible
hemorrhages. Hypoxia leads to the production of oxygen free
radicals via the activation of neutrophils,[25] such as in ischaemia-
reperfusion trauma. These radicals are harmful to the endothelium
and increase vascular permeability.[26] Loss of vasomotor control
may further contribute to the damage of the retinal vessels.[27]
Although these pathophysiological changes were studied in
conditions with extensive ischaemia (e.g. surgical procedures), we
suggest that due to the exceptionally low oxygen saturation during
the climb, this process, even though less pronounced than in total
ischaemia, may explain the enhanced occurrence of hemorrhages
after descent. The extent of hypoxia during a high altitude climb
may determine the morphology of HAR.
Drug intake was shown to have no impact on retinal bleeding in
our study. However, only small amounts of different medications
were taken by our climbers, which might not have been enough to
relevantly influence our analysis.
HAR is most probably the result of systemic hypoxic effects on
the eye despite regulatory attempts by the retinal and choroidal
circulation. According to our statistical analysis, parameters
characterizing ocular circulation, such as retinal and choroidal
blood flow and retinal arterial or venous calibers did not play a
valid explanatory role for retinal bleeding during a high altitude
expedition.
According to our analysis, higher hematocrit, possibly repre-
senting higher blood viscosity, correlated positively with the
number of hemorrhages. Elevated blood viscosity may increase
shear stress to the predamaged retinal vascular endothelial cells.
High altitude retinopathy and its possible etiologies have been
described by many authors [28,29,30]. A classification for HAR
has been established by Wiedman et al.[12]
Although optic disc swelling, which occurred in both groups
with ascent to higher altitudes and regressed upon descent, was
shown to correlate with total area of hemorrhages during the
expedition, the course of these parameters differed at BC2 where
almost all optic disc swelling had regressed.[15] Both optic disc
swelling and HAR are signs of overall susceptibility to hypoxia.
Nevertheless, since reaction of the optic disc to hypoxia is quicker
than that of potential retinal hemorrhages, a grading of HAR
implying a direct correlation with cerebral attenuation is not
warranted. Such a grading of HAR should primarily include optic
disc swelling rather than number and area of hemorrhages.
Singling out climbers with HACE, no difference in number or area
Table 3. Results of multiple regression analysis performed with total number and total area of hemorrhages and various
independent predictors.
Independent predictors: Total number of hemorrhages Total area of hemorrhages
Beta p-value Beta p-value
SpO2 20.40 ,0.001 20.42 ,0.001
Hematocrit 0.22 0.002 0.23 0.001
Time at Altitude 0.33 0.003 0.30 0.006
Optic disc swelling 0.13 0.08 0.17 0.019
AMS-c score 20.09 0.15 20.12 0.06
Age 20.09 0.13 20.1 0.13
SpO2 20.38 ,0.001 20.40 ,0.001
BFS-V 20.13 0.07 20.11 0.12
Perfusion Pressure 20.05 0.42 20.09 0.15
LDF-Flow 0.06 0.29 0.03 0.65
arterial diameter 20.12 0.19 20.06 0.49
venous diameter 0.01 0.91 0.03 0.73
doi:10.1371/journal.pone.0011532.t003
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of hemorrhages in comparison to the mountaineers without
HACE was detected. This is another indicator that HAR has no
prognostic value for cerebral attenuation during a high altitude
expedition.
Many reports on high altitude climbing show persistence of
symptoms such as scotomas[30] and visual field shrinkage.[31] We
found no such sequelae in our climbers 4.5 months after the
expedition, nor any signs of visual disturbances during the
expedition except for the climber with vitreous hemorrhages in
one eye. This may be attributed to the observation that the vast
majority of retinal hemorrhages occurred near the optic disc
hardly affecting the macula.
Despite the impressive number of ocular changes at high
altitudes, it seems that they are mostly transient. We suggest that
the number of retinal hemorrhages rather than the total area of
bleeding is a delayed marker of overall degree of hypoxic
exposure. Also, due to latency of their appearance, retinal
hemorrhages should not be considered warning signs of impending
severe AMS or HACE. Based on our data, we cannot confirm that
the current classification of HAR can be used as a predictor of
progressive altitude illness.
Acknowledgments
We would like to thank our hematology group with Andreas Huber, MD,
for their significant efforts concerning hematocrit measurements, Alexan-
der Turk, MD, Otto Schoch, MD, Thomas Hess, MD, and Gregor
Schubiger, MD, for their unwavering support during the expedition. Also
included in this thanks are Kari Kobler and his team of mountain guides
and porters, who contributed largely to the safe and successful sojourn on
Mt Muztagh Ata. Thanks to Horst Helbig, MD, for his valuable help with
the manuscript. Thanks also to our photography team Ursula Gautschy,
Danica Stojcic and Peter Ba¨r at the University Hospital of Zurich.
This work was presented in part at the North American Neuro-
Ophthalmology Society (NANOS) Meeting in Lake Tahoe, Nevada,
U.S.A. February 21–26, 2009 (Poster 61) and ARVO, Fort Lauderdale,
Florida, U.S.A. May 1–7, 2009 (e-Abstract 72).
Author Contributions
Conceived and designed the experiments: DB MMB BLP MM KL.
Performed the experiments: DB MMB FT TAH. Analyzed the data: DB
MMB TMM BLP FT KEB TAH PC UH MS FKS MM KL. Contributed
reagents/materials/analysis tools: DB MMB TMM BLP FT KEB PC UH
FKS MM KL. Wrote the paper: DB MMB MM KL. Substantial
contributions to analysis and interpretation of data: TMM KEB TAH MS
FKPS. Drafting the article or revising it critically for important intellectual
content: TMM KEB TAH MS FKPS. Final approval of the version to be
published: TMM BLP FT KEB TAH PC UH MS FKPS.
References
1. Singh I, Khanna PK, Srivastava MC, Lal M, Roy SB, et al. (1969) Acute
mountain sickness. N Engl J Med 280: 175–184.
2. Frayser R, Houston CS, Bryan AC, Rennie ID, Gray G (1970) Retinal
hemorrhage at high altitude. N Engl J Med 282: 1183–1184.
3. Hackett PH, Roach RC (2001) High-altitude illness. N Engl J Med 345:
107–114.
4. Schneider M, Bernasch D, Weymann J, Holle R, Bartsch P (2002) Acute
mountain sickness: influence of susceptibility, preexposure, and ascent rate. Med
Sci Sports Exerc 34: 1886–1891.
5. Bloch KE, Turk AJ, Maggiorini M, Hess T, Merz T, et al. (2009) Effect of ascent
protocol on acute mountain sickness and success at Muztagh Ata, 7546 m. High
Alt Med Biol 10: 25–32.
6. Roach R, Ba¨rtsch P, Oelz O, Hackett P, Committee LLASC (1993) The Lake
Louise acute mountain sickness scoring system. In: Sutton JR, Houston CS,
Coates G, eds. Hypoxia and molecular medicine (Baltimore). pp 272–274.
7. Wilson MH, Newman S, Imray CH (2009) The cerebral effects of ascent to high
altitudes. Lancet Neurol 8: 175–191.
8. McFadden DM, Houston CS, Sutton JR, Powles AC, Gray GW, et al. (1981)
High-altitude retinopathy. JAMA 245: 581–586.
9. Delaey C, Van De Voorde J (2000) Regulatory mechanisms in the retinal and
choroidal circulation. Ophthalmic Res 32: 249–256.
10. Patton N, Aslam T, Macgillivray T, Pattie A, Deary IJ, et al. (2005) Retinal
vascular image analysis as a potential screening tool for cerebrovascular disease:
a rationale based on homology between cerebral and retinal microvasculatures.
J Anat 206: 319–348.
11. Clarke C, Duff J (1976) Mountain sickness, retinal haemorrhages, and
acclimatisation on Mount Everest in 1975. Br Med J 2: 495–497.
12. Wiedman M, Tabin GC (1999) High-altitude retinopathy and altitude illness.
Ophthalmology 106: 1924–1926. discussion 1927.
13. Jansen GF, Kagenaar DA, Basnyat B, Odoom JA (2002) Basilar artery blood
flow velocity and the ventilatory response to acute hypoxia in mountaineers.
Respir Physiol Neurobiol 133: 65–74.
14. Hackett PH, Yarnell PR, Hill R, Reynard K, Heit J, et al. (1998) High-altitude
cerebral edema evaluated with magnetic resonance imaging: clinical correlation
and pathophysiology. JAMA 280: 1920–1925.
15. Bosch MM, Barthelmes D, Merz T, Bloch KE, Turk AJ, et al. (2008) High
Incidence of Optic Disc Swelling at Very High Altitudes. Arch Ophthalmol 126:
1–7.
16. Bosch MM, Merz TM, Barthelmes D, Petrig BL, Truffer F, et al. (2009) New
insights into ocular blood flow at very high altitudes. J Appl Physiol 106:
454–460.
17. Geiser MH, Diermann U, Riva CE (1999) Compact Laser Doppler Choroidal
Flowmeter. Journal of Biomedical Optics 4: 459–464.
18. Riva CE, Cranstoun SD, Grunwald JE, Petrig BL (1994) Choroidal blood flow
in the foveal region of the human ocular fundus. Invest Ophthalmol Vis Sci 35:
4273–4281.
19. Bosch MM, Barthelmes D, Merz TM, Truffer F, Knecht PB, et al. Intraocular
pressure during a very high altitude climb. Invest Ophthalmol Vis Sci 51:
1609–1613.
20. Hayreh SS (2001) The blood supply of the optic nerve head and the evaluation
of it - myth and reality. Prog Retin Eye Res 20: 563–593.
21. Maggiorini M, Muller A, Hofstetter D, Bartsch P, Oelz O (1998) Assessment of
acute mountain sickness by different score protocols in the Swiss Alps. Aviat
Space Environ Med 69: 1186–1192.
22. Ling R, James B (1998) White-centred retinal haemorrhages (Roth spots).
Postgrad Med J 74: 581–582.
23. Roth M (1872) U¨ber Netzhautaffectionen bei Wundfiebern. I. Die embolische
Panophthalmitis. Deutsche Zeitschrift fu¨r Chirurgie 1: 471–484.
24. Duane TD, Osher RH, Green WR (1980) White centered hemorrhages: their
significance. Ophthalmology 87: 66–69.
25. Freischlag JA, Hanna D (1991) Superoxide anion release (O2-) after ischemia
and reperfusion. J Surg Res 50: 565–568.
26. Gryglewski RJ, Palmer RM, Moncada S (1986) Superoxide anion is involved in
the breakdown of endothelium-derived vascular relaxing factor. Nature 320:
454–456.
27. Van Osta A, Moraine JJ, Melot C, Mairbaurl H, Maggiorini M, et al. (2005)
Effects of high altitude exposure on cerebral hemodynamics in normal subjects.
Stroke 36: 557–560.
28. Frayser R, Houston CS, Gray GW, Bryan AC, Rennie ID (1971) The response
of the retinal circulation to altitude. Arch Intern Med 127: 708–711.
29. Rennie D, Morrissey J (1975) Retinal changes in Himalayan climbers. Arch
Ophthalmol 93: 395–400.
30. Shults WT, Swan KC (1975) High altitude retinopathy in mountain climbers.
Arch Ophthalmol 93: 404–408.
31. Wiedman M (1975) High altitude retinal hemorrhage. Arch Ophthalmol 93:
401–403.
Retinal Hemorrhages
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e11532
